Improvement in Highly Active Antiretroviral Therapy--Induced Metabolic Syndrome by Treatment with Pioglitazone but Not with Fenofibrate: A 2 x 2 Factorial, Randomized, Double-Blinded, Placebo-Controlled Trial

• DOI: 10.1086/427697
• Publication Date: 2005-02-17T00:10:41Z
• Authors: A. Gavrila; W. Hsu; S. Tsiodras; J. Doweiko; S. Gautam; L. Martin; A. C. Moses; A. W. Karchmer; C. S. Mantzoros
• Keywords: Pioglitazone; Fenofibrate; Double blinded

We designed a 2 × factorial, randomized, double-blinded, placebo-controlled trial to evaluate the effects of treatment with pioglitazone and/or fenofibrate in patients highly active antiretroviral therapy (HAART)–induced metabolic syndrome. found that administration pioglitazone, but not fenofibrate, improved insulin resistance, blood pressure, and lipid profile over 12-month period.